Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

964
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
964
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

822
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
822
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

733
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
733
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

932
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
932

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State of the Art of Artificial Intelligence in Clinical Electrophysiology in 2025: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), and the ESC Working Group on E-Cardiology.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2025
Same author

[Legal aspects in digital cardiology].

Herz·2024
Same author

Publisher Erratum: The Heart Failure Optimization Study (HF‑OPT): rationale and design.

Herzschrittmachertherapie & Elektrophysiologie·2023
Same author

The Heart Failure Optimization Study (HF-OPT): rationale and design.

Herzschrittmachertherapie & Elektrophysiologie·2023
Same author

[Canalopathies, arrhythmogenic right ventricular cardiomyopathy and artefacts].

Herzschrittmachertherapie & Elektrophysiologie·2019
Same author

Is CGRP Receptor Blockade Cardiovascularly Safe? Appropriate Studies Are Needed.

Headache·2018

Related Experiment Video

Updated: Jun 21, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K

[Antiarrhythmic drugs in the present day].

R Allgaier1, D Duncker2

  • 1Hannover Herzrhythmus Centrum, Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.

Innere Medizin (Heidelberg, Germany)
|July 15, 2024
PubMed
Summary

This article reviews common antiarrhythmic drugs for treating cardiac arrhythmias, focusing on safe and effective use in outpatient settings. It details drug handling, contraindications, side effects, and interactions for long-term and acute management.

Keywords:
Antiarrhythmic drugs/interactionsAntiarrhythmic drugs/safety aspectsAtrial fibrillationSupraventricular tachycardiaVentricular tachycardia

More Related Videos

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice
06:07

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice

Published on: May 23, 2021

3.6K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K

Related Experiment Videos

Last Updated: Jun 21, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K
Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice
06:07

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice

Published on: May 23, 2021

3.6K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiac arrhythmias are a leading cause of global hospitalizations and medical visits.
  • Antiarrhythmic drugs are crucial for managing arrhythmias, reducing recurrence, and treating conditions like atrial fibrillation and heart failure.

Purpose of the Study:

  • To provide a comprehensive overview of prevalent antiarrhythmic medications.
  • To offer guidance on the appropriate use and management of these drugs, particularly in outpatient environments.
  • To highlight essential considerations for safe and effective antiarrhythmic therapy.

Main Methods:

  • Review of common antiarrhythmic drugs.
  • Analysis of their applications in both long-term and acute arrhythmia management.
  • Examination of contraindications, side effects, and drug interactions.

Main Results:

  • Identified common antiarrhythmic drugs and their therapeutic uses.
  • Outlined recommendations for handling and administration, emphasizing outpatient care.
  • Stressed the importance of monitoring for contraindications, adverse effects, and interactions.

Conclusions:

  • Effective and safe treatment of cardiac arrhythmias requires careful consideration of antiarrhythmic drug properties.
  • Patient monitoring is essential to mitigate risks associated with potent antiarrhythmic medications.
  • This overview aims to ensure optimal patient outcomes through informed drug management.